The Series A round included backing from British Patient Capital, F-Prime Capital, and Sofinnova Partners.
"Tenpoint Therapeutics has been built on the pioneering work of its scientific founders who are recognised leaders in ocular therapies. Their vision combined with research excellence provides the best foundation to develop treatments that could be gamechangers for millions of patients worldwide. Through Future Fund: Breakthrough, we are delighted to support this truly innovative British business with the funding to take the business to the next level."
The London scaleup will use the capital to scale its presence in the United States and broaden its artificial intelligence offerings.
"AI represents one of the biggest leaps forward in technology in recent years and our unique approach to data sourcing from humans positions us to make these systems more accountable and less biased. The funding we have secured will fuel our growth in the AI space, especially in the US, bolstering our commitment to human-guided AI development during this pivotal moment in the technology’s progression."
The financing was backed by Delin Ventures, AlbionVC, Playfair Capital and 11.2 Capital to support international growth and research programmes.
"We developed the uMed platform to help healthcare professionals more easily and efficiently run patient research and targeted care programmes at scale, improving outcomes for patients by mitigating care gaps and accelerating research. Our groundbreaking patient cohorts give researchers access to unique data and insights, accelerating development and access to new therapies, while dramatically reducing the cost of finding, engaging and collecting prospective data from patients."
AXA Venture Partners led the Series A round with backing from Seedcamp to help accelerate product development and international growth.
"We’re delighted to be partnering with AVP. We work heavily in the finance sector and we’re proud to partner with a household financial services brand. AVP is a perfect partner for us to grow within other regulated domains and geographies with AVP’s global reach."
The Cambridge-based synthetic gene provider raised the capital from Mercia Ventures to expand operations and develop its DNA synthesis platform.
"We are delighted to have closed this latest round of funding with Mercia, which provides further validation of Camena’s approach. The ability to read, write and manipulate DNA is the foundation of the synthetic biology value chain, yet developments in DNA synthesis have not kept pace with DNA sequencing and editing capabilities. Camena’s gSynth platform is revolutionising the DNA synthesis market by unlocking access to genes and accelerating discovery pipelines. As the focus on sustainability and supply-chain security become more acute, Camena is leading the way with a green synthesis technology and is already well positioned to serve this burgeoning market. The invention of next-generation DNA sequencing technologies transformed our ability to ‘read’ DNA. Our goal is to enable our customers to ‘write’ DNA with the same confidence and ease."
